NURIX THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.55 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-05-31 was -$263.00K.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-02-28 was -$1.29M, a 120.59% decline year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-11-30 was $1.28M, a 4.73% increase year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-08-31 was $1.98M, a 247.89% increase year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $6.23M, a 1257.08% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $459.00K.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$2.14M, a 295.52% decline from fiscal 2022.
- NURIX THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.09M, a 79.90% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$1.55M 10-Q · filed 2026-07-09 | -$266.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.72M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | -$1.29M 10-Q · filed 2026-04-08 | -$3.00K derived: sum of 2 quarters · filed 2026-04-08 | $1.98M derived: sum of 3 quarters · filed 2026-04-08 | -$1.31M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.27M derived: sum of 2 quarters · filed 2026-01-28 | -$23.00K derived: sum of 3 quarters · filed 2026-07-09 | $6.23M 10-K · filed 2026-01-28 |
| 2025-08-31 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$1.31M derived: sum of 2 quarters · filed 2026-07-09 | $4.95M 10-Q · filed 2025-10-09 | $6.17M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $2.96M 10-Q · filed 2026-07-09 | $4.19M derived: sum of 3 quarters · filed 2026-07-09 | $4.76M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $6.25M 10-Q · filed 2026-04-08 | $7.48M derived: sum of 2 quarters · filed 2026-04-08 | $8.05M derived: sum of 3 quarters · filed 2026-04-08 | $7.88M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $1.80M derived: sum of 2 quarters · filed 2026-01-28 | $1.63M derived: sum of 3 quarters · filed 2026-01-28 | $459.00K 10-K · filed 2026-01-28 |
| 2024-08-31 | $570.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $401.00K derived: sum of 2 quarters · filed 2025-10-09 | -$767.00K 10-Q · filed 2025-10-09 | -$350.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$169.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | -$1.34M 10-Q · filed 2025-07-09 | -$920.00K derived: sum of 3 quarters · filed 2026-01-28 | -$2.96M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$1.17M 10-Q · filed 2025-04-08 | -$751.00K derived: sum of 2 quarters · filed 2026-01-28 | -$2.79M derived: sum of 3 quarters · filed 2026-01-28 | -$4.93M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$1.62M derived: sum of 2 quarters · filed 2026-01-28 | -$3.77M derived: sum of 3 quarters · filed 2026-01-28 | -$2.14M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | -$4.18M derived: sum of 2 quarters · filed 2024-10-11 | -$2.56M 10-Q · filed 2024-10-11 | -$3.71M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | -$515.00K 10-Q · filed 2024-07-11 | -$1.67M derived: sum of 3 quarters · filed 2025-01-28 | -$936.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $1.63M 10-Q · filed 2024-04-10 | $471.00K derived: sum of 2 quarters · filed 2025-01-28 | $1.21M derived: sum of 3 quarters · filed 2025-01-28 | $1.21M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$421.00K derived: sum of 2 quarters · filed 2025-01-28 | -$420.00K derived: sum of 3 quarters · filed 2025-01-28 | $1.09M 10-K · filed 2025-01-28 |
| 2022-08-31 | $735.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $736.00K derived: sum of 2 quarters · filed 2023-10-12 | $2.25M 10-Q · filed 2023-10-12 | $1.65M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $1.51M 10-Q · filed 2023-07-13 | $917.00K derived: sum of 3 quarters · filed 2023-07-13 | $6.12M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $1.51M 10-Q · filed 2023-04-13 | $916.00K derived: sum of 2 quarters · filed 2023-04-13 | $6.12M derived: sum of 3 quarters · filed 2023-04-13 | $8.29M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | -$598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $4.61M derived: sum of 2 quarters · filed 2023-02-09 | $6.78M derived: sum of 3 quarters · filed 2023-02-09 | $5.44M 10-K · filed 2023-02-09 |
| 2021-08-31 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $7.38M derived: sum of 2 quarters · filed 2022-10-06 | $6.04M 10-Q · filed 2022-10-06 | $5.59M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $837.00K 10-Q · filed 2022-07-07 | $384.00K derived: sum of 3 quarters · filed 2022-07-07 | $2.72M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | -$1.33M 10-Q · filed 2022-04-08 | -$1.79M derived: sum of 2 quarters · filed 2022-04-08 | $550.00K derived: sum of 3 quarters · filed 2022-04-08 | -$1.07M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | -$453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $1.89M derived: sum of 2 quarters · filed 2022-01-28 | $265.00K derived: sum of 3 quarters · filed 2022-01-28 | $3.94M 10-K · filed 2022-01-28 |
| 2020-08-31 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $718.00K derived: sum of 2 quarters · filed 2021-10-14 | $4.39M 10-Q · filed 2021-10-14 | $4.13M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | -$1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $2.06M 10-Q · filed 2021-07-13 | $1.79M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $3.68M 10-Q · filed 2021-04-13 | $3.41M derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | -$268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $15.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $283.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |